首页> 外文期刊>Biotechnology Advances: An International Review Journal >Development of health biotechnology in developing countries: Can private-sector players be the prime movers?
【24h】

Development of health biotechnology in developing countries: Can private-sector players be the prime movers?

机译:发展中国家卫生生物技术的发展:私营企业可以成为主要推动者吗?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Health biotechnology has rapidly become vital in helping healthcare systems meet the needs of the poor in developing countries. This key industry also generates revenue and creates employment opportunities in these countries. To successfully develop biotechnology industries in developing nations, it is critical to understand and improve the system of health innovation, as well as the role of each innovative sector and the linkages between the sectors. Countries' science and technology capacities can be strengthened only if there are non-linear linkages and strong interrelations among players throughout the innovation process; these relationships generate and transfer knowledge related to commercialization of the innovative health products. The private sector is one of the main actors in healthcare innovation, contributing significantly to the development of health biotechnology via knowledge, expertise, resources and relationships to translate basic research and development into new commercial products and innovative processes. The role of the private sector has been increasingly recognized and emphasized by governments, agencies and international organizations. Many partnerships between the public and private sector have been established to leverage the potential of the private sector to produce more affordable healthcare products. Several developing countries that have been actively involved in health biotechnology are becoming the main players in this industry. The aim of this paper is to discuss the role of the private sector in health biotechnology development and to study its impact on health and economic growth through case studies in South Korea, India and Brazil. The paper also discussed the approaches by which the private sector can improve the health and economic status of the poor.
机译:在帮助医疗保健系统满足发展中国家穷人的需求方面,健康生物技术已迅速变得至关重要。这个关键行业还在这些国家创造收入并创造就业机会。为了成功地在发展中国家发展生物技术产业,了解和改善卫生创新体系,每个创新部门的作用以及这些部门之间的联系至关重要。只有在整个创新过程中参与者之间存在非线性联系和强有力的相互联系,才能加强国家的科学和技术能力;这些关系产生并转移了与创新保健产品商业化有关的知识。私营部门是医疗保健创新的主要参与者之一,它通过知识,专长,资源和关系将基础研究和开发转化为新的商业产品和创新过程,为健康生物技术的发展做出了重要贡献。政府,机构和国际组织日益认识到并强调了私营部门的作用。已经建立了公共部门和私营部门之间的许多伙伴关系,以利用私营部门的潜力来生产更多负担得起的保健产品。几个积极参与健康生物技术的发展中国家正在成为该行业的主要参与者。本文的目的是通过韩国,印度和巴西的案例研究,探讨私营部门在健康生物技术发展中的作用,并研究其对健康和经济增长的影响。本文还讨论了私营部门改善穷人的健康和经济状况的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号